| Basics |
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals Inc is an integrated biopharmaceutical company. It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
|
| IPO Date: |
April 2, 1991 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$61.38B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$4.20 | 1.81%
|
| Avg Daily Range (30 D): |
$11.95 | 2.00%
|
| Avg Daily Range (90 D): |
$11.45 | 1.74%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.66M |
| Avg Daily Volume (30 D): |
.8M |
| Avg Daily Volume (90 D): |
.73M |
| Trade Size |
| Avg Trade Size (Sh.): |
65 |
| Avg Trade Size (Sh.) (30 D): |
28 |
| Avg Trade Size (Sh.) (90 D): |
27 |
| Institutional Trades |
| Total Inst.Trades: |
10,898 |
| Avg Inst. Trade: |
$17.67M |
| Avg Inst. Trade (30 D): |
$53.2M |
| Avg Inst. Trade (90 D): |
$51.33M |
| Avg Inst. Trade Volume: |
.05M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$34.85M |
| Avg Closing Trade (30 D): |
$101.27M |
| Avg Closing Trade (90 D): |
$97.33M |
| Avg Closing Volume: |
71.06K |
|
|
|
|
| Financials |
| |
TTM |
Q4 2024 |
FY 2024 |
|
Basic EPS
|
$40.9
|
$8.54
|
$40.9
|
|
Diluted EPS
|
$38.34
|
$8.11
|
$38.34
|
|
Revenue
|
$ 14.2B
|
$ 3.79B
|
$ 14.2B
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ 4.41B
|
$ 917.7M
|
$ 4.41B
|
|
Operating Income / Loss
|
$ 3.99B
|
$ 990.2M
|
$ 3.99B
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ -248.8M
|
$ 477.2M
|
$ -248.8M
|
|
PE Ratio
|
16.02
|
|
|
|
